ATEZOLIZUMAB (Tecentriq) prior authorization at Blue Cross Blue Shield of Michigan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross Blue Shield of Michigan requires Programmed Death Receptor-1 Blocking Antibody prior-authorization documentation for ATEZOLIZUMAB (Tecentriq): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Blue Cross Blue Shield of Michigan reviews ATEZOLIZUMAB (Tecentriq) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody. Blue Cross Blue Shield of Michigan-specific context: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross Blue Shield of Michigan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Step therapy via OptumRx (PBM since 2024)
- Site-of-care reductions for infusions
- Behavioral health prior auth
- OON balance bill disputes
ATEZOLIZUMAB (Tecentriq)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Triple-negative breast cancer indication (voluntarily withdrawn 2021 — plans cite this for all TNBC denials)
- SCLC maintenance denial
- Off-label NSCLC combinations
Brand: Tecentriq. PD-L1 inhibitor. SubQ formulation (Tecentriq Hybreza) FDA-approved September 2024. Note: TNBC accelerated approval withdrawn August 2021 — be careful citing this indication in appeals.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Blue Cross Blue Shield of Michigan denial sticks and the patient needs bridge access while appealing.
How Blue Cross Blue Shield of Michigan approaches Immune checkpoint inhibitors PAs
For ATEZOLIZUMAB (TECENTRIQ), check the current Blue Cross Blue Shield of Michigan Immune checkpoint inhibitors policy for NCCN compendium citation for the specific tumor type, PD-L1 testing where label-required, and combination-partner medical necessity. Pharmacy-benefit review for ATEZOLIZUMAB (TECENTRIQ) at Blue Cross Blue Shield of Michigan is routed through OptumRx (switched from Express Scripts January 2024). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Blue Cross Blue Shield of Michigan; if denied, use the filing date and route printed on that denial notice. Off-label oncology appeals at Blue Cross Blue Shield of Michigan carry significantly higher reversal rates when the appeal letter cites the specific NCCN compendium evidence-block category (2A or above) rather than peer-reviewed citations alone. Blue Cross Blue Shield of Michigan is domiciled in MI, so unresolved appeals escalate to the MI insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://providers.bcbsm.com) with the same packet plus an applicable, current clinical source supporting ATEZOLIZUMAB (Tecentriq)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross Blue Shield of Michigan denial on DenialHelp.
Contact Blue Cross Blue Shield of Michigan
- Provider portal: https://providers.bcbsm.com
Frequently asked questions
What documentation does Blue Cross Blue Shield of Michigan need for ATEZOLIZUMAB (Tecentriq) prior auth?
Blue Cross Blue Shield of Michigan's typical PA packet for ATEZOLIZUMAB (Tecentriq): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Blue Cross Blue Shield of Michigan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for ATEZOLIZUMAB (Tecentriq) at Blue Cross Blue Shield of Michigan?
Preparation scenarios to check against the current notice and policy include: Step therapy via OptumRx (PBM since 2024); Site-of-care reductions for infusions; Behavioral health prior auth. These are not measured frequency claims. For ATEZOLIZUMAB (Tecentriq), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does Blue Cross Blue Shield of Michigan cover off-label use of ATEZOLIZUMAB (TECENTRIQ) supported by NCCN compendium?
Blue Cross Blue Shield of Michigan may consult the NCCN Drugs & Biologics Compendium for oncology coverage. For off-label ATEZOLIZUMAB (TECENTRIQ), cite the current compendium entry by version and table, name the evidence-block category, and attach the supporting clinical-trial or meta-analysis reference. Verify the member-specific coverage rule and timing before relying on this preparation guide. Pharmacy-benefit handling is routed through OptumRx (switched from Express Scripts January 2024). External-review escalation for Blue Cross Blue Shield of Michigan fully-insured policies sits with the MI insurance department.
How do I prep for a peer-to-peer with Blue Cross Blue Shield of Michigan on ATEZOLIZUMAB (Tecentriq)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Blue Cross Blue Shield of Michigan
- Aflibercept at Blue Cross Blue Shield of Michigan
- Apixaban at Blue Cross Blue Shield of Michigan
- Atogepant at Blue Cross Blue Shield of Michigan
- ATEZOLIZUMAB (Tecentriq) at UnitedHealthcare
- ATEZOLIZUMAB (Tecentriq) at Elevance Health
- ATEZOLIZUMAB (Tecentriq) at Aetna
Generate the ATEZOLIZUMAB (Tecentriq) PA packet
Open ApprovalHelp — generate a ATEZOLIZUMAB (Tecentriq) prior-auth packet tailored to Blue Cross Blue Shield of Michigan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com